Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 28.01.2021.

#biotechnology
#COVID19
#biospace
#lifesciences
#pharmaceuticals
#coronavirus
#COVID
#clinicaltrials
#vaccine
#treatment

Companies And Industries

@biospace shared
On Jan 26, 2021
2021 Biopharma Update on the Novel Coronavirus: January 26 #biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/Ol87b8Wyws
Open
2021 Biopharma Update on the Novel Coronavirus: January 26

2021 Biopharma Update on the Novel Coronavirus: January 26

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.

@pfizer shared
On Jan 26, 2021
RT @FierceBiotech: “R&D should be rewarded with risks,” Dolsten said, but added that when companies like Moderna are given huge lump sums, “we are doing R&D without the risks. For a pandemic, that may be OK, but it really isn’t the way we should use resources as a society” https://t.co/oIm097cUXK
Open
Pfizer's R&D president Dolsten: Not taking government cash made us more nimble for COVID-19 vaccine

Pfizer's R&D president Dolsten: Not taking government cash made us more nimble for COVID-19 vaccine

Mikael Dolsten, M.D., Ph.D., Pfizer’s chief scientific officer and president for worldwide R&D and medical, is clear: The company's COVID-19 vaccine is here because of a decade of R&D work ...

@biospace shared
On Jan 27, 2021
@jpmorgan Will Biotech’s Virtual 2021 Launch Become the New Reality? #biospace #lifesciences #biotechnology #pharmaceuticals https://t.co/AGsOIjIqZX
Open
J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?

J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?

At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually.  And, as is becoming the common scenario, attendees found both pros ...

@BiotechWorld shared
On Jan 23, 2021
Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post https://t.co/F3gQNMxdp7 https://t.co/9VyU7UPSmB
Open
Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

Amir Reichman, global vaccines engineering core technology at GSK, is stepping down to pursue a CEO role at BiondVax. Covance's Maryland Franklin is stepping up to run Covance's cell and ...

@pharmaphorum shared
On Jan 25, 2021
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with #ulcerativecolitis following a major disappointment with a key lung cancer drug last week https://t.co/utga1T1W6u #pharma
Open
GSK suffers another R&D setback, axing ulcerative colitis drug trial

GSK suffers another R&D setback, axing ulcerative colitis drug trial

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key ...

@FierceBiotech shared
On Jan 22, 2021
This is not curtains for the whole program, and the GSK license for the drug “remains in place,” Immutep said, although the British Big Pharma is now assessing “next steps” for the program https://t.co/Ea5J9PgdKg
Open
GlaxoSmithKline's R&D failures rack up, notching an Immutep-partnered trial cull

GlaxoSmithKline's R&D failures rack up, notching an Immutep-partnered trial cull

It’s not been a great week for GlaxoSmithKline’s partnered R&D projects; after being forced to cull a major lung cancer trial with Merck KGaA, it’s now a case of déjà vu as it axes yet ...

@LillyPad shared
On Jan 27, 2021
New: Lilly, @Vir_Biotech and @GSKUS announce a collaboration to evaluate two therapies together in low-risk patients with mild to moderate #COVID19. Learn more: https://t.co/Jx5ke6iHiZ https://t.co/x3SozBMxAM
Open
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

@ErnestoChanona shared
On Jan 27, 2021
RT @BioBuzzMaryland: Six life science companies to keep an eye on in 2021 and beyond https://t.co/f1Cph2u8Pv https://t.co/toKeVnSJ6A
Open
Six Biotechs to Watch in 2021

Six Biotechs to Watch in 2021

By investing over $77M, HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs, ITI is well-positioned to accelerate its immuno-oncology platform, …

Read more: Companies And Industries
weekly 28.01.2021
View archives
Back to home